Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with the University of Washington in de novo drug discovery using a ubiquitination platform. BeyondSpring's lead asset, Plinabulin, is in two Phase 3 global clinical trials as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to the global market.
We have a novel, highly scalable business model that integrates clinical resources in the U.S. and China. We believe that our strategy of dual development in both the U.S. and China has provided and will continue to provide significant advantages including the ability to conduct trials in China, which could result in faster enrollment, lower costs, expedited approval process, as well as access to China's fast growing cancer market. Our drug development capabilities are facilitated by strong interest from clinical investigators in the U.S. as well as by our understanding of the pharmaceutical industry, clinical resources and regulatory system in China.
BeyondSpring is listed on Nasdaq with ticker BYSI.